Immunicon (IMMC) Awarded Research Services Agreement with Bristol-Myers
Immunicon Corporation (NASDAQ: IMMC) entered into a Research Services Agreement with Bristol-Myers Squibb (NYSE: BMY) involving protein and molecular targets associated with circulating tumor cells.
Create E-mail AlertRelated Categories
Corporate NewsStocks Mentioned
-0.09
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
